All In Biotech

Drug Trial Radar · NCT02656173

A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)

A Phase 4, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Mirabegron in Japanese and Korean Male Patients With Overactive Bladder Under Treatment With the α-Blocker Tamsulosin for Benign Prostatic Hyperplasia

Last checked: Nov 20, 2026Latest source record: Nov 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 568 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

568

Actual

Start

Jan 25, 2016

Primary completion

Jul 21, 2017

Study completion Jul 21, 2017

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
Collaborators
Astellas Pharma Singapore Pte. Ltd.
First posted
Jan 14, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study was to investigate the efficacy of mirabegron versus placebo in male patients with OAB symptoms while taking the alpha blocker, tamsulosin, for BPH.

Conditions

  • Overactive Bladder

Interventions

  • MirabegronDrug

    Oral tablet

  • PlaceboDrug

    Oral tablet

  • TamsulosinDrug

    Oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to End of Treatment (EoT) in Mean Number of Micturitions Per 24 HoursTime frame: Baseline and EoT (up to 12 weeks)
  2. Change From Baseline to Weeks 4, 8, 12 in Mean Number of Micturitions Per 24 HoursTime frame: Baseline and week 4, 8 and 12

Locations

58 sites in 2 countries. Site status is shown where the registry gives one.

  • Site JP81046

    Aichi, Japan

  • Site JP81009

    Chiba, Japan

  • Site JP81045

    Chiba, Japan

  • Site JP81041

    Fukuoka, Japan

  • Site JP81042

    Fukuoka, Japan

  • Site JP81043

    Fukuoka, Japan

  • Site JP81044

    Fukuoka, Japan

  • Site JP81048

    Fukuoka, Japan

  • Site JP81004

    Gunma, Japan

  • Site JP81005

    Gunma, Japan

  • Site JP81001

    Hokkaido, Japan

  • Site JP81002

    Hokkaido, Japan

  • Site JP81003

    Hokkaido, Japan

  • Site JP81038

    Hyōgo, Japan

  • Site JP81039

    Hyōgo, Japan

  • Site JP81040

    Hyōgo, Japan

  • Site JP81024

    Kanagawa, Japan

  • Site JP81056

    Kanagawa, Japan

  • Site JP81051

    Kochi, Japan

  • Site JP81052

    Kochi, Japan

  • Site JP81047

    Kumamoto, Japan

  • Site JP81025

    Osaka, Japan

  • Site JP81026

    Osaka, Japan

  • Site JP81027

    Osaka, Japan

  • Site JP81028

    Osaka, Japan

  • Site JP81029

    Osaka, Japan

  • Site JP81030

    Osaka, Japan

  • Site JP81031

    Osaka, Japan

  • Site JP81032

    Osaka, Japan

  • Site JP81033

    Osaka, Japan

  • Site JP81034

    Osaka, Japan

  • Site JP81035

    Osaka, Japan

  • Site JP81036

    Osaka, Japan

  • Site JP81037

    Osaka, Japan

  • Site JP81053

    Osaka, Japan

  • Site JP81054

    Osaka, Japan

  • Site JP81006

    Saitama, Japan

  • Site JP81007

    Saitama, Japan

  • Site JP81008

    Saitama, Japan

  • Site JP81050

    Shizuoka, Japan

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.